Moreover, neuroinflammatory diseases such as Parkinson’s disease are characterized by an aberrant activation of the JAK/STAT pathway and can therefore be potentially treated with JAK/STAT inhibitors [167]. This evidence concerns the gene SOAT1 and Parkinson disease.